| Autor: |
Stevens KL; Department of Oncology, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. Kirk.L.Stevens@gsk.com, Reno MJ, Alberti JB, Price DJ, Kane-Carson LS, Knick VB, Shewchuk LM, Hassell AM, Veal JM, Davis ST, Griffin RJ, Peel MR |
| Jazyk: |
angličtina |
| Zdroj: |
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2008 Nov 01; Vol. 18 (21), pp. 5758-62. Date of Electronic Publication: 2008 Sep 24. |
| DOI: |
10.1016/j.bmcl.2008.09.069 |
| Abstrakt: |
A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect